Cargando…

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients

Detalles Bibliográficos
Autores principales:	Trivedi, Sumita, Srivastava, Raghvendra M, Concha-Benavente, Fernando, Garcia-Bates, Tatiana M, Li, Jing, Ferris, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649444/ http://dx.doi.org/10.1186/2051-1426-3-S2-P316

Ejemplares similares

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
por: Concha-Benavente, Fernando, et al.
Publicado: (2017)

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
por: Concha-Benavente, Fernando, et al.
Publicado: (2015)

EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3
por: Concha-Benavente, Fernando, et al.
Publicado: (2013)

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
por: Mazorra, Zaima, et al.
Publicado: (2017)

STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
por: Srivastava, Raghvendra M, et al.
Publicado: (2013)

STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer
por: Lu, Shanhong, et al.
Publicado: (2018)

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
por: Modjtahedi, H., et al.
Publicado: (1996)

EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer
por: Ma, Wenbo, et al.
Publicado: (2018)

Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model
por: Srivastava, Raghvendra M, et al.
Publicado: (2015)

Monoclonal Antibodies and Toxins—A Perspective on Function and Isotype
por: Chow, Siu-Kei, et al.
Publicado: (2012)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
por: Li, Jing, et al.
Publicado: (2015)

Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy
por: Fasano, Morena, et al.
Publicado: (2021)

Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
por: Kaneko, Mika K., et al.
Publicado: (2018)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

In reply to “Anti-alpha-enolase antibodies in membranous nephropathy: isotype matters”
por: Imai, Hirokazu, et al.
Publicado: (2016)

Idiotope regulation by isotype switch variants of two monoclonal antiidiotope antibodies
Publicado: (1984)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

Monoclonal antibodies against bovine immunoglobulins and their use in isotype-specific ELISAs for rotavirus antibody
por: Van Zaane, Dick, et al.
Publicado: (1984)

Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells
por: Gao, Yang, et al.
Publicado: (2014)

EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex
por: Lei, Yu, et al.
Publicado: (2016)

Domain binding and isotype dictate the activity of anti-human OX40 antibodies
por: Griffiths, Jordana, et al.
Publicado: (2020)

Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants
por: Walters, Adam A., et al.
Publicado: (2022)

Preparation and characterization of monoclonal antibodies recognizing two CD4 isotypes of Microminipigs
por: Ohshima, Shino, et al.
Publicado: (2020)

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
por: Negri, D. R., et al.
Publicado: (1995)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
por: Morales-Estevez, Cristina, et al.
Publicado: (2016)

The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients
por: van Delft, Myrthe A. M., et al.
Publicado: (2017)

Cellular cytotoxicity mediated by isotype-switch variants of a monoclonal antibody to human neuroblastoma.
por: d'Uscio, C. H., et al.
Publicado: (1991)

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response
por: Boeckx, Carolien, et al.
Publicado: (2014)

Importance of immunoglobulin isotype in human antibody-dependent, cell- mediated cytotoxicity directed by murine monoclonal antibodies
Publicado: (1985)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
por: van Helden, E. J., et al.
Publicado: (2017)

Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2020)

A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
por: Ferris, Robert L, et al.
Publicado: (2015)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Development of anti-citrullinated protein antibody and rheumatoid factor isotypes prior to the onset of rheumatoid arthritis
por: Bos, Wouter H, et al.
Publicado: (2014)

Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis
por: Cabrera-Villalba, Sonia, et al.
Publicado: (2017)

IgA is the predominant isotype of anti‐β2 glycoprotein I antibodies in rheumatoid arthritis
por: Melayah, Sarra, et al.
Publicado: (2020)

Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis
por: Castellanos-Moreira, Raul, et al.
Publicado: (2020)

Isotyping and Semi-Quantitation of Monkey Anti-Drug Antibodies by Immunocapture Liquid Chromatography-Mass Spectrometry
por: Huang, Xiaoxiao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kqkbofk6458og97g61p5lg0abc